Results 121 to 130 of about 17,663 (255)

Clinical Outcomes of Non Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Non Valvular Atrial Fibrillation Patients: A Cohort Study in a Rural Tertiary Care Hospital, Gujarat, India

Journal of Clinical and Diagnostic Research
Introduction: Atrial Fibrillation (AF) is the most common arrhythmia, with an increased risk of ischaemic stroke and subsequent morbidity and mortality. Oral anticoagulants such as Vitamin K Antagonists (VKAs) and non VKA Oral Anticoagulants (NOACs) are ...
Sohilkhan Riyazkhan Pathan, Bharat M Gajjar, Sunilkumar Karna, Kushal Pujara   +3 more
doaj   +1 more source

Non-vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis

Kardiologia Polska, 2019
Oral anticoagulants (OACs) are widely used for prevention of systemic thromboembolism, including the reduction of the risk of stroke in patients with atrial fibrillation (AF) and prosthetic heart valves. There is also an increasing population of patients who require not only OACs, but also double antiplatelet therapy (DAPT).
Adam, Witkowski, Marcin, Barylski, Krzysztof J, Filipiak, Marek, Gierlotka, Jacek, Legutko, Maciej, Lesiak, Janina, Stępińska, Wojciech, Wojakowski   +7 more
openaire   +3 more sources

Emerging risk factors influencing the occurrence of peri‐implantitis

Periodontology 2000, EarlyView.
Abstract Background The objective of the present review is to explore the evidence and biological plausibility of factors that may expose dental implants to a greater likelihood of developing peri‐implantitis. Material and Methods An electronic screening on the PubMed library the was carried out to identify potential emerging factors that influence the
Alberto Monje, Ronald E. Jung, Cristina Valles, Nadja Naenni   +3 more
wiley   +1 more source

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures

Transfusion, EarlyView.
Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Mohammad Shamiea, Alex Osnis, Awan Kashoua, Orli Avnery, Gilad Itchaki, Shuli Isman, Tali Tohami, Osnat Jarchowsky‐Dolberg, Martin Ellis   +8 more
wiley   +1 more source

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.

PLoS ONE, 2015
BackgroundUse of the non-vitamin K antagonist oral anticoagulants (NOACs) is endorsed by current guidelines for stroke prevention in patients with atrial fibrillation (AF).
Giuseppe Santarpia, Salvatore De Rosa, Alberto Polimeni, Salvatore Giampà, Mariella Micieli, Antonio Curcio, Ciro Indolfi   +6 more
doaj   +1 more source

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey

BJGP Open, 2018
Background: Familiarity and competency in the options for stroke prevention in atrial fibrillation (AF) and the role of non-vitamin K antagonist oral anticoagulants (NOACs) may vary among primary care physicians (PCPs) from different European countries ...
Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan Polo Friz, David Fitzmaurice, FD Richard Hobbs   +5 more
doaj   +1 more source

Prebiotic Bimuno® GOS reduces illness symptoms and supports gut barrier function and immunity after intermittent exercise in the heat

Experimental Physiology, EarlyView.
Abstract Exercise in hot climates increases the risk of gastrointestinal (GI) disruption and respiratory illness. We investigated the effects of a 42 day prebiotic intervention on markers of intestinal epithelial injury, GI discomfort and immunity following football specific exercise in the heat and daily upper respiratory illness.
Connor J. Parker, Samantha J. Abbott, Luke R. Butterfield, Kirsty A. Hunter, Michael A. Johnson, Graham R. Sharpe, Neil C. Williams   +6 more
wiley   +1 more source

The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study

American Journal of Hematology, Volume 101, Issue 6, Page 1379-1387, June 2026.
ABSTRACT Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020.
Abhilasha Borad, Michael Andersen Jr., Danielle Guffey, Hanqing Shang, Jun Y. Jiang, Maria J. Fernandez Turizo, Jonathan Berry, Jeffrey I. Zwicker, Rushad Patell, Ang Li   +9 more
wiley   +1 more source

Proper dosing and key drug interactions of the non-vitamin K antagonist oral anticoagulants. Summary from the 2024 European Society of Cardiology (ESC) Guidelines

Cardiologia Hungarica
The use of non-vitamin K antagonist oral anticoagulants (NOACs) has become a cornerstone of stroke prevention in patients with atrial fibrillation. This brief summary, based on the latest European guidelines, aims to summarize the appropriate dosing ...
Letícia Kazareczki, Máté Vámos
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source